Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $8.1400 (-2.51%) ($8.0400 - $8.4500) on Thu. Aug. 27, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 16.22% (three month average) | RSI | 55 | Latest Price | $8.1400(-2.51%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.5% a day on average for past five trading days. | Weekly Trend | ADAP advances 1.9% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XLRE(24%) DRIV(23%) IWC(23%) XBI(23%) IWM(22%) | Factors Impacting ADAP price | ADAP will decline at least -8.11% in a week (0% probabilities). BNDX(-16%) TLT(-14%) TIP(-11%) BND(-11%) VXX(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -8.11% (StdDev 16.22%) | Hourly BBV | 0 () | Intraday Trend | -3.7% | | | |
|
Resistance Level | $8.47 | 5 Day Moving Average | $8.39(-2.98%) | 10 Day Moving Average | $8.52(-4.46%) | 20 Day Moving Average | $8.47(-3.9%) | To recent high | -32.7% | To recent low | 3.6% | Market Cap | $1.259b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |